Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis
ICD-10 N01.4 is a billable code used to indicate a diagnosis of rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis.
Rapidly progressive nephritic syndrome (RPNS) is characterized by a swift decline in renal function, often leading to end-stage renal disease if not promptly treated. This syndrome is associated with diffuse endocapillary proliferative glomerulonephritis, which is marked by the proliferation of glomerular endothelial cells and inflammatory cells within the capillary loops. Clinically, patients present with symptoms of nephritis, including hematuria, proteinuria, and hypertension. Laboratory findings typically reveal significant proteinuria, often exceeding 3.5 grams per day, and the presence of red blood cell casts in the urine. Renal biopsy is crucial for diagnosis, revealing glomerular hypercellularity and often immune complex deposition. Management of RPNS involves addressing the underlying cause, which may include immunosuppressive therapy, corticosteroids, and supportive care for renal function. Early intervention is critical to prevent irreversible kidney damage.
Detailed clinical notes on symptoms, lab results, and treatment plans.
Patients presenting with acute kidney injury, hematuria, and proteinuria.
Ensure all relevant lab results and imaging studies are documented to support the diagnosis.
Comprehensive reports on renal biopsy findings, including histological details.
Biopsy evaluations for suspected glomerulonephritis.
Pathology reports should clearly indicate the type of glomerular disease to support nephrology coding.
Used when a renal biopsy is performed to confirm diagnosis.
Document indication for biopsy, findings, and any complications.
Nephrology specialists should ensure biopsy results are linked to the diagnosis.
Key symptoms include hematuria, proteinuria, hypertension, and rapid decline in renal function.
Diagnosis is typically made through clinical evaluation, laboratory tests showing proteinuria and hematuria, and renal biopsy confirming glomerular pathology.
